FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD


January 11, 2018

In This Article

Baxdela (delafloxacin)


Acute skin and skin structure infections caused by certain aerobic gram-positive and gram-negative bacteria, including methicillin-resistant and methicillin-sensitive S aureus strains.


Fluoroquinolone antibiotic; inhibits both bacterial topoisomerase IV and DNA gyrase (topoisomerase II) enzymes, which are required for bacterial DNA replication, transcription, repair, and recombination.


300 mg IV q12hr for 5-14 days, OR

300 mg IV q12hr, then switch to a 450-mg tablet PO q12hr for 5-14 days, OR

450 mg PO q12hr for 5-14 days


Approval was based on two phase 3 trials in patients with acute bacterial skin and skin structure infections (ABSSSI) demonstrating that IV and oral delafloxacin monotherapy was statistically noninferior to the combination of vancomycin plus aztreonam at the FDA primary endpoint of early clinical response at 48–72 hr.


Baxdela (delafloxacin) prescribing information. Melinta Therapeutics, Inc. Lincolnshire, IL. June 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.